- Home
- RARE vs SXI Comparison
RARE vs SXI Comparison
Compare RARE & SXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | SXI |
|---|---|---|
| Founded | 2010 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | SXI |
|---|---|---|
| Price | $34.13 | $230.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 3 |
| Target Price | $85.20 | ★ $264.00 |
| AVG Volume (30 Days) | ★ 1.6M | 155.0K |
| Earning Date | 02-12-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.36 |
| Revenue | $630,598,000.00 | ★ $837,074,000.00 |
| Revenue This Year | $19.09 | $15.51 |
| Revenue Next Year | $20.62 | $7.04 |
| P/E Ratio | ★ N/A | $51.69 |
| Revenue Growth | ★ 20.63 | 18.51 |
| 52 Week Low | $25.81 | $128.85 |
| 52 Week High | $46.50 | $252.78 |
Technical Indicators
Market Signals| Indicator | RARE | SXI |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 47.27 |
| Support Level | $32.64 | $217.08 |
| Resistance Level | $35.12 | $252.78 |
| Average True Range (ATR) | 1.44 | 9.14 |
| MACD | -0.27 | -1.57 |
| Stochastic Oscillator | 22.07 | 35.21 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About SXI Standex International Corporation
Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.